The response rate in the breast cancer cohort (n = 20) was 33%, and clinically relevant activity was also observed in HER2-positive gastroesophageal adenocarcinoma and subjects with other HER2-positive solid tumours (ORR 44% and 33%, respectively). This evidence concerns the gene ERBB2 and breast carcinoma.